Difference between revisions of "Team:Kent/HP/Silver"

 
(14 intermediate revisions by the same user not shown)
Line 188: Line 188:
 
         margin: auto;
 
         margin: auto;
 
         margin-bottom:200px;
 
         margin-bottom:200px;
−
         margin-top:50px;
+
         margin-top:0px;
 
         width: 1200px;
 
         width: 1200px;
 
opacity:0.85;
 
opacity:0.85;
Line 348: Line 348:
 
#textbox2{
 
#textbox2{
 
display:inline-block;
 
display:inline-block;
−
margin: 40px 0 40px 0;
+
margin: 0px 0 0px 0;
 
width:1000px;
 
width:1000px;
 
border-radius:20px;
 
border-radius:20px;
Line 359: Line 359:
 
}
 
}
  
 +
}
 +
.connector{
 +
text-align:center;
 +
}
 +
.connector img{
 +
display:inline-block;
 +
width:50px;
 +
}
  
 
#box1 p{
 
#box1 p{
Line 373: Line 381:
 
}
 
}
  
−
 
+
#title2{
 +
padding: 50px 0 50px 0;
 +
}
 
.centerizer{
 
.centerizer{
 
width:100%;
 
width:100%;
 
text-align:center;
 
text-align:center;
−
margin: 50px 0 50px 0;
+
margin: 0 0 0 0;
 
}
 
}
 
.centerizer span{
 
.centerizer span{
Line 532: Line 542:
 
<img src = "https://static.igem.org/mediawiki/2017/thumb/1/12/T--Kent--SilverHeader2.png/766px-T--Kent--SilverHeader2.png" id="header2">
 
<img src = "https://static.igem.org/mediawiki/2017/thumb/1/12/T--Kent--SilverHeader2.png/766px-T--Kent--SilverHeader2.png" id="header2">
 
         </div>
 
         </div>
−
         <nav class="droptext arrows">
+
          
−
<header class="hull">
+
−
<label for="acc-close" class="hull-title">Basic Protocols</label>
+
−
</header>
+
 
<div id="box1">
 
<div id="box1">
−
<div class="centerizer">
 
−
<span>London Meetup</span>
 
−
<div class="SlineSeparator"></div>
 
  
−
</div>
 
  
−
 
+
<div id="textbox2" >
−
<div id="textbox1" >
+
 
<p>Our team has strived to make human practices the solid foundation of our project right from the start. We wanted to ensure we fully understood the implications of any project we chose to pursue while addressing current global problems.  
 
<p>Our team has strived to make human practices the solid foundation of our project right from the start. We wanted to ensure we fully understood the implications of any project we chose to pursue while addressing current global problems.  
 
<br>
 
<br>
Line 552: Line 554:
 
</div>
 
</div>
  
−
<div class="centerizer">
+
<div class="centerizer"  id="title2">
−
<span>Judd High School</span>
+
<span>Why CRISPR-dCas13a (C2C2)?</span>
 
<div class="SlineSeparator"></div>
 
<div class="SlineSeparator"></div>
 
</div>
 
</div>
 +
 
<div id="box2">
 
<div id="box2">
  
 
<div id="textbox2" >
 
<div id="textbox2" >
−
<p>This year, three members of our team: Laulwa Al Salloum, Laurens Heling and Dan Brunkow, were able to work alongside Team Judd_UK in the InterLab study. They were able to use our lab and equipment to obtain the necessary readings for their InterLab while we mentored two of their members; Nikita Shukan and Mateo Hoare through the process, as well as aiding them in their managing of the different aspects of the study, such as: using the Gilson pipettes, using the plate reader, incubating the samples, etc. In return, they generously donated their InterLab DNA from Distribution kit plate 6 for us to transform as we were unsuccessful in transforming the DNA from our own kit into the E.coli DH5 alpha cells.
+
<p>We were introduced to CRISPR-Cas9 as a tool for targeting cellular mRNA translation through Dr. Peter Ellis, a lecturer in Molecular Biology and Reproduction. However, through research, we discovered that Cas9 is a DNA endonuclease, meaning it recognizes DNA targets and cuts them. It would need to be ‘tricked’ by molecular means. C2C2, however, or Cas13a is an RNA endonuclease, meaning it cuts the RNA rather than the DNA. There are two key differences when comparing Cas13 to CAS9: Firstly, Cas13 recognizes RNA rather than DNA. Secondly, once the target is recognized, it acts promiscuously and starts to ‘chew up’ all of the RNA around it, not only the intended target sequence. <br><img src="https://static.igem.org/mediawiki/2017/3/3c/T--Kent--LogbookP5.png"><img src="https://static.igem.org/mediawiki/2017/5/52/T--Kent--LogbookP3.png">
−
<br>
+
−
Being able to work alongside another iGEM team was incredibly useful in viewing the study from a different point of view as Judd_UK were experiencing all the lab work for the first time as they are a High School team. Being able to mentor them allowed us to work through the study step by step until it became second nature to perform all the readings.
+
−
<br>
+
−
Link to Judd’s wiki on our collaboration: https://2017.igem.org/Team:Judd_UK/Collaborations
+
 
</p>
 
</p>
 
</div>
 
</div>
−
<div id="textbox4" >
+
<div class="centerizer">
−
<img src="https://static.igem.org/mediawiki/2017/9/9e/T--Kent--Collaboration3.png">
+
<div class="connector">
 +
<img src="https://static.igem.org/mediawiki/2017/thumb/f/f4/T--Kent--HP9.png/133px-T--Kent--HP9.png">
 
</div>
 
</div>
 +
<div id="textbox2" >
 +
<p>
 +
We wanted to utilize this knowledge and build upon the CRISPR-Cas9 and produce a tool that would just track the mRNA, not cut it. We did not want to overcomplicate our methodology and deemed tagging the mRNA with GFP would be sufficient as we would be able to essentially track the mRNA movement to ensure its localization without damaging its integrity through cutting it.
 +
</p>
 +
</div>
 +
</div>
 +
<div class="centerizer">
 +
<div class="connector">
 +
<img src="https://static.igem.org/mediawiki/2017/thumb/f/f4/T--Kent--HP9.png/133px-T--Kent--HP9.png">
 +
</div>
 +
</div>
 +
<nav class="droptext arrows">
 +
<header class="hull">
 +
<label for="acc-close" class="hull-title">Surveys and Consultations</label>
 +
</header>
 +
<input type="radio" name="droptext" id="cb1" />
 +
<section class="hull">
 +
<label class="hull-title" for="cb1">Surveys</label>
 +
<label class="hull-close" for="acc-close"></label>
 +
<div class="hull-content"><ul><li>We wanted the opportunity to receive insight from the public immediately, even before deciding on a project idea. We wanted to ensure that any topic we would be putting our focus into would heed positive results, not only from the scientific community but from the general public as well.</li>
 +
 +
<li>We set out to design several surveys, questioning the community at our University and locally on their knowledge of GMOs and whether our project abstract was an idea they agreed would be beneficial once produced. </li>
 +
 +
<li>The general consensus from the students at the University was that they agreed genetic modification would be beneficial when used appropriately, however strict regulations would need to be in place when dealing with GMO applications, a small percentage even saying they would go the extra mile to ensure they did not deal with GMOs in their day to day lives.</li>
 +
<li><img src="https://static.igem.org/mediawiki/2017/e/e8/T--Kent--HP1.png"></li>
 +
<li>With this in mind, we introduced our project abstract and explained the positive outcomes we saw it producing and its potential as a diagnostic tool. The majority of the feedback we received was positive and allowed us to confidently advance in our laboratory work with a goal in mind: produce a tool with a promising future in diagnositcs.
 +
</li>
 +
<li><img src="https://static.igem.org/mediawiki/2017/d/d9/T--Kent--HP2.png"><img src="https://static.igem.org/mediawiki/2017/6/60/T--Kent--HP3.png"></li>
 +
<li><img src="https://static.igem.org/mediawiki/2017/8/84/T--Kent--HP4.png"></li>
 
</div>
 
</div>
 +
</section>
 +
<input type="radio" name="droptext" id="acc-close" />
 +
<input type="radio" name="droptext" id="cb2" />
 +
<section class="hull">
 +
<label class="hull-title" for="cb2">Professor Michelle Garrett</label>
 +
<label class="hull-close" for="acc-close"></label>
 +
<div class="hull-content">When conceptualizing our project, we realized we would need to transfect our cell lines into mammalian cells if we wanted to have any use of it as a potential diagnostic tool, as it would be relatively useless in its bacterial cell host. Professor Garrett was able to guide us in the direction of the Smales Group at our University, providing us with the resources needed to make the transfections possible.<br><img src="https://static.igem.org/mediawiki/2017/2/2b/T--Kent--HP8.png"></div>
 +
</section>
 +
<input type="radio" name="droptext" id="acc-close" />
 +
<input type="radio" name="droptext" id="cb3" />
 +
<section class="hull">
 +
<label class="hull-title" for="cb3">Ian Brown, Microscopy Suite Facility Manager</label>
 +
<label class="hull-close" for="acc-close"></label>
 +
<div class="hull-content">As CRISPR itself has only recently been discovered as an mRNA tracking tool, most of the project entailed repeated trial and error. We realized before we even thought of imaging, we needed to ensure we had the appropriate controls for comparative and evaluative reasons. We were able to generate a repeatable layout for future imaging purposes that Ian Brown was able to confirm would be adequate in imaging our cells accurately<br>
 +
<img src="https://static.igem.org/mediawiki/2017/9/9d/T--Kent--HP5.png"></div>
 +
</section>
 +
<input type="radio" name="droptext" id="acc-close" />
 +
<input type="radio" name="droptext" id="cb4" />
 +
<section class="hull">
 +
<label class="hull-title" for="cb4">Dr. Emma Mead</label>
 +
<label class="hull-close" for="acc-close"></label>
 +
<div class="hull-content">Through research, we were able to conclude the best possible cells to transfect our constructs into would have to be HEK293 cells. However, without experience in such a field, we were guided to Dr. Mead, who proved to be invaluable throughout the entirety of our project. She confirmed that it would indeed have to be the HEK293 cells and provided us with samples to work with, as well as guiding us through the passaging and transfection itself.<br>
 +
<img src="https://static.igem.org/mediawiki/2017/5/5a/T--Kent--HP6.png"></div>
 +
</section>
 +
<input type="radio" name="droptext" id="acc-close" />
 +
<input type="radio" name="droptext" id="cb5" />
 +
<section class="hull">
 +
<label class="hull-title" for="cb5">Dr. Rosalyn Masterton</label>
 +
<label class="hull-close" for="acc-close"></label>
 +
<div class="hull-content">We were able to conclude that we would need a vector to clone our construct before we could image it and decided upon pcDNA 3.1 (+) mammalian vector through the help of Dr. Masterton with her expertise in molecular biology. She also advised us who to speak to for the use of mammalian cell lines.<br>
 +
<img src="https://static.igem.org/mediawiki/2017/b/bf/T--Kent--HP7.png"></div>
 +
</section>
 +
<input type="radio" name="droptext" id="acc-close" />
  
 +
</nav>
  
 
         <div id="foot">
 
         <div id="foot">

Latest revision as of 03:03, 16 December 2017


Integrated HP

Our team has strived to make human practices the solid foundation of our project right from the start. We wanted to ensure we fully understood the implications of any project we chose to pursue while addressing current global problems.
We held a brainstorming session where we bounced ideas off of one another for potential project ideas and had narrowed it down to a top five. We decided we needed to consult with our immediate community to scope out what issues they deemed important that needed immediate addressing. Through different outreach opportunities, we were able to comprehend the controversy surrounding GMOs and genetic engineering in general. This caused us to critically analyze our project ideas before deciding upon ‘LuCAS’: a novel way of mRNA localization using CRISPR - dCas13a.

Why CRISPR-dCas13a (C2C2)?

We were introduced to CRISPR-Cas9 as a tool for targeting cellular mRNA translation through Dr. Peter Ellis, a lecturer in Molecular Biology and Reproduction. However, through research, we discovered that Cas9 is a DNA endonuclease, meaning it recognizes DNA targets and cuts them. It would need to be ‘tricked’ by molecular means. C2C2, however, or Cas13a is an RNA endonuclease, meaning it cuts the RNA rather than the DNA. There are two key differences when comparing Cas13 to CAS9: Firstly, Cas13 recognizes RNA rather than DNA. Secondly, once the target is recognized, it acts promiscuously and starts to ‘chew up’ all of the RNA around it, not only the intended target sequence.

We wanted to utilize this knowledge and build upon the CRISPR-Cas9 and produce a tool that would just track the mRNA, not cut it. We did not want to overcomplicate our methodology and deemed tagging the mRNA with GFP would be sufficient as we would be able to essentially track the mRNA movement to ensure its localization without damaging its integrity through cutting it.